Overview

Trial of Celecoxib With Preoperative Chemo- Radiation for Locally Advanced Rectal Cancer

Status:
Completed
Trial end date:
2013-04-01
Target enrollment:
Participant gender:
Summary
This is a single arm phase II trial with combined celecoxib, tegafur-uracil, folinate and preoperative radiotherapy for patients with locally advanced rectal cancer. The primary end point is pathological complete response (pCR) rate. The secondary endpoints are toxicities of combined celecoxib and chemoradiation, negative resection margin rate, clinical tumor response by magnetic resonance imaging (MRI), sphincter preservation rate, disease-free survival and overall survival.
Phase:
Phase 2
Details
Lead Sponsor:
National Health Research Institutes, Taiwan
Collaborators:
Chang Gung Memorial Hospital
Changhua Christian Hospital
Chi Mei Medical Hospital
Mackay Memorial Hospital
National Cheng-Kung University Hospital
Taichung Veterans General Hospital
Taipei Veterans General Hospital, Taiwan
Treatments:
Celecoxib